Cargando…
Biopharmaceutical Financialization and Public Funding of Medical Countermeasures (MCMs) in Canada During the COVID-19 Pandemic
Background: Analysing the Canadian government’s efforts to support the development of COVID-19 "medical countermeasures" (MCMs), this article seeks insights into political economy as a driver of pandemic response. We explore whether Canadian public funding policy during the pandemic involv...
Autores principales: | Eren Vural, Ipek, Herder, Matthew, Doll, Agnieszka, Graham, Janice E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Kerman University of Medical Sciences
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462233/ https://www.ncbi.nlm.nih.gov/pubmed/37579382 http://dx.doi.org/10.34172/ijhpm.2023.6936 |
Ejemplares similares
-
From sandbox to pandemic: Agile reform of Canadian drug regulation()
por: Eren Vural, Ipek, et al.
Publicado: (2021) -
Transparency too little, too late? Why and how Health Canada should make clinical data and regulatory decision-making open to scrutiny in the face of COVID-19
por: Edmonds, Sterling, et al.
Publicado: (2020) -
The Changing Landscape for New Drug Development: Medical Countermeasures (MCMs) as a Case Study
por: Milne, Christopher-Paul
Publicado: (2019) -
MCMs in Cancer: Prognostic Potential and Mechanisms
por: Yu, Si, et al.
Publicado: (2020) -
The Funding of Biopharmaceutical Research and Development
por: Williams, D
Publicado: (2013)